2seventy bio’s (TSVT) Sell (D-) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research report released on Wednesday,Weiss Ratings reports.

2seventy bio Stock Performance

Shares of NASDAQ TSVT opened at $2.57 on Wednesday. The firm has a market capitalization of $132.59 million, a P/E ratio of -1.38 and a beta of 1.74. 2seventy bio has a one year low of $2.29 and a one year high of $6.40. The company’s fifty day moving average is $2.72 and its two-hundred day moving average is $3.85.

Institutional Trading of 2seventy bio

A number of institutional investors have recently modified their holdings of TSVT. Erste Asset Management GmbH purchased a new position in 2seventy bio in the 3rd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. purchased a new position in 2seventy bio in the 4th quarter worth approximately $32,000. BNP Paribas Financial Markets purchased a new position in shares of 2seventy bio during the 4th quarter valued at approximately $35,000. ProShare Advisors LLC purchased a new position in shares of 2seventy bio during the 4th quarter valued at approximately $48,000. Finally, Raymond James Financial Inc. purchased a new position in shares of 2seventy bio during the 4th quarter valued at approximately $52,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.